Table 2.
Potential predictive markers for sensitivity or resistance to OVs.
| OV | Potential Predictive Marker | Effect | Tumor Type/ Cell Line |
|---|---|---|---|
| T-VEC | STING | Resistance | Melanoma cell lines [104] |
| Adenovirus (Ad5/3-Δ24) |
MxA | Resistance | Ovarian carcinoma cell line [110] |
| High HMGB1 | Resistance | Patients with advanced metastatic solid tumors [112] | |
| (Δ24-RGD) | Cyclin D1 | Sensitivity | Pancreatic cell line [113] |
| Vocimagene amiretrorepvec | IDH1, PI3K3CA, EGFR, SYNE1 Neo-epitopes |
Sensitivity | Patients with recurrent high-grade gliomas [118] |
| NK cells and M0 macrophage tumor infiltration | Resistance | Patients with recurrent high-grade gliomas [118] | |
| MV | IFITM1 | Resistance | Transformed mesenchymal stromal cells [124] |
| RIG-I | Resistance | Sarcoma cells [125] | |
| ISG15 | Resistance | Primary GBM cells [123] | |
| NDV | Bcl-xl | Sensitivity | A549 cell line [128] |
| Rac-1 | Sensitivity | HaCaT A5-RT3 [132] | |
| STAT3 | Sensitivity | Melanoma cell lines [129] | |
| Reovirus (R124) | JAM-A | Sensitivity | Primary GBM cells [56] |
| Cathepsin B | Sensitivity | Glioma cell line [144] | |
| P53 and EGFR mutations | Sensitivity | Patients with non-small cell lung cancer [145] | |
| Ki-67 | Sensitivity | Patients with high grade gliomas and metastatic brain tumors [136] | |
| Oncolytic parvovirus H-1 | Cathepsin B | Sensitivity | Glioma cell line [18,151] |
| Vaccinia virus | Expression of ILT2 on T cells | Resistance | Melanoma patients [155] |
| LEF1, STAMBPL1, and SLFN11 | Sensitivity | myeloid and lymphoid leukemia cell lines [156] | |
| PVRIG, LPP, CECR1, Arhgef6, IRX3, IGFBP2, and CD1d | Resistance | myeloid and lymphoid leukemia cell lines [156] |